85561-97-3

Basic information

• Product Name: 1H-Benzimidazole-2,5-diamine(9CI)
• Synonyms: 1H-Benzimidazole-2,5-diamine(9CI);1H-Benzimidazole-2,5-diamine;1H-benzo[d]iMidazole-2,5-diaMine;3H-benzimidazole-2,5-diamine
• CAS NO: 85561-97-3
• Molecular Formula: C₇H₈N₄
• Molecular Weight: 148.17
• Product Categories: BENZIMIDAZOLE;pharmacetical
• Mol File: 85561-97-3.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 476.6°C at 760 mmHg
• Flash Point: 273.5°C
• Appearance: /
• Density: 1.486g/cm³
• Vapor Pressure: 3E-09mmHg at 25°C
• Refractive Index: 1.865
• PKA: 10.80±0.10(Predicted)
• CAS DataBase Reference: 1H-Benzimidazole-2,5-diamine(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Benzimidazole-2,5-diamine(9CI)(85561-97-3)
• EPA Substance Registry System: 1H-Benzimidazole-2,5-diamine(9CI)(85561-97-3)

Safety Data

• Hazardous Substances Data: 85561-97-3(Hazardous Substances Data)

Usage

Appearance

White crystalline solid

Usage

a. Synthesis of pharmaceuticals and organic compounds
b. Building block for potential drugs in medicinal chemistry
c. Production of dyes, pigments, and other industrial products

Applications

a. Research in medicinal chemistry
b. Industrial applications

Chemical and Biological Activities

Wide range of activities making it important in research and industrial applications.

InChI:InChI=1/C7H8N4/c8-4-1-2-5-6(3-4)11-7(9)10-5/h1-3H,8H2,(H3,9,10,11)

Upstream product

• 203302-73-2 2-chloro-1H-benzo[d]imidazol-5-amine 
• 4857-06-1 2-chloro-1H-benzoimidazole 
• 5955-72-6 2-chloro-5-nitro-1H-benzo[d]imidazole 
• 24370-22-7 2-amino-4-nitro-1H-benzimidazole 
• 506-68-3 bromocyane 
• 615-71-4 benzene-1,2,4-triamine 
• 6232-92-4 2-amino-5-nitrobenzimidazole 
• 6232-92-4 6-nitro-1H-benzo[d]imidazol-2-amine 

Relevant articles and documents

5-SULFAMOYL-2-HYDROXYBENZAMIDE DERIVATIVES

The invention is directed to substituted salicylamide derivatives. Specifically, the invention is directed to compounds according to Formula (I): wherein R, R1 and R2 are as defined herein, or a pharmaceutically acceptable salt thereof. The compounds of the invention are inhibitors of CD73 and can be useful in the treatment of cancer, pre-cancerous syndromes and diseases associated with CD73 inhibition, such as AIDS, the treatment of HIV, autoimmune diseases, infections, atherosclerosis, and ischemia–reperfusion injury. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting CD73 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

The design, synthesis and biological evaluation of 7-alkoxy-4-heteroarylamino-3-cyanoquinolines as dual inhibitors of c-Src and iNOS

Because both c-Src and iNOS are key regulatory enzymes in tumorigenesis, a new series of 4-heterocycle amine-3-quinolinecarbonitriles as potent dual inhibitors of both enzymes were designed, synthesized and evaluated as multiple targets agents in cancer therapy. All compounds were evaluated by two related enzyme inhibition assays and an anti-proliferation assay in vitro. The results showed that most compounds inhibited c-Src and iNOS well. The best compound 8 inhibited both enzymes with the IC50 values of 34.8 nM and 26.7 μM. Several compounds also showed moderate anti-proliferation at 10 μM against colon and liver cancer cell lines.

Polyamide analogs

This invention is directed to novel antibacterial/antifungal/antiparasitic agents of Formula (I): pharmaceutical compositions containing them, methods for their use and methods for preparing these compound